Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save your life!

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

Researchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...